ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Evaluation of effectiveness and safety of polaprezinc as an adjuvant therapy in enhancing fracture healing in adults with closed fractures: a prospective study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fracture healing is a complex biological process that can be delayed by systemic or local factors. Polaprezinc, a zinc-L-carnosine complex with antioxidant, anti-inflammatory, and regenerative properties, has shown promise in tissue repair, but its role in bone regeneration remains underexplored. To evaluate the effectiveness and safety of polaprezinc as an adjuvant therapy in enhancing fracture healing among adults with closed fractures. A prospective, single-center, controlled, non-randomized interventional study was conducted over a 3 months period at a tertiary care hospital in Hyderabad. A total of 100 adults (18-85 years) with radiologically confirmed closed fractures were assigned to two groups: an intervention group receiving standard orthopedic care plus oral polaprezinc (75 mg twice daily) and a control group receiving standard care alone. Clinical outcomes were assessed using the Visual Analogue Scale (VAS) for pain and weight-bearing ability, while radiological outcomes were measured using the Radiographic Healing Scale (RHS) and REBORNE Scale at 4, 8, and 12 weeks. Safety was monitored through laboratory tests and adverse event reporting. The polaprezinc group demonstrated significantly faster radiological union and stronger callus formation compared with controls (RHS and REBORNE scores, p < 0.05). Pain reduction was greater in the intervention group (VAS improvement: t = 5.696, p < 0.05). Mean fracture healing time was shortened by approximately one week. No serious adverse events were reported, and compliance was high. Polaprezinc as an adjunct to standard fracture care significantly improved radiological and clinical healing outcomes, reduced pain, and maintained an excellent safety profile. These findings support its potential as a safe and effective adjuvant in fracture management, warranting confirmation in larger multicenter trials.
Indexed as
Identifiers
41902855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.